The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.
Bien S, Riad A, Ritter CA, Gratz M, Olshausen F, Westermann D, Grube M, Krieg T, Ciecholewski S, Felix SB, Staudt A, Schultheiss HP, Ewert R, Völker U, Tschöpe C, Kroemer HK.
Bien S, et al. Among authors: ritter ca.
Cancer Res. 2007 Nov 1;67(21):10428-35. doi: 10.1158/0008-5472.CAN-07-1344.
Cancer Res. 2007.
PMID: 17974986